1 / 40

Douglas S. Scherr, M.D. Weill Medical College of Cornell University

Minimally Invasive Approaches in the Treatment of Urothelial Carcinoma “ Robotic Radical Cystectomy ”. Douglas S. Scherr, M.D. Weill Medical College of Cornell University. Robotics Beyond The Prostate. Radical Cystectomy Can we achieve equal oncological outcome?. Radical Cystectomy.

nickan
Download Presentation

Douglas S. Scherr, M.D. Weill Medical College of Cornell University

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Minimally Invasive Approaches in the Treatment of Urothelial Carcinoma“Robotic Radical Cystectomy” Douglas S. Scherr, M.D. Weill Medical College of Cornell University

  2. Robotics Beyond The Prostate • Radical Cystectomy • Can we achieve equal oncological outcome?

  3. Radical Cystectomy • Gold Standard for Invasive Disease • Role in T1 Disease • Quality of surgery impacts outcome and survival

  4. Was the Effect all Chemotherapy?Are surgical variables important? • Post cystectomy survival predicted by: a.) age b.) stage c.) node status d.) negative surgical margins e.) >10 nodes removed • Hazard ratio for death: a.) 2.7 for + surgical margin b.) 2.0 for <10 nodes removed Herr et al. JCO, 22(14): 2781, 2004

  5. Radical Cystectomy for T1 TCC • USC Experience: 208 pts with T1 disease • USC Experience with T2 disease Recurrence Free Survival Overall Survival 5 Year 10 Year 5 Year 10 Year 80% 75% 74% 51% Recurrence Free Survival Overall Survival 5 Year 10 Year 5 Year 10 Year 81% 80% 72% 56% Stein et al., J Clin Oncol, 19(3): 666-75, 2001

  6. Early Vs. Late Cystectomy • 90 pts who had TUR + BCG ultimately underwent cystectomy • 41/90 had T1 disease • Median Follow up of 96 mos Early cystectomy (<2 years): 92% survival Late cystectomy (>2 years): 56% survival Herr and Sogani, J Urol, 166: 1296-9, 2001

  7. Extent of Lymphadenectomy • Is there more to the node dissection than staging? • 1936 Colston and Leadbetter performed studies on 98 cadavers “limited metastatic disease was restricted to the pelvic nodes” • 1946 – Dr. Jewett “cardinal site of metastasis” Colston and Leadbetter, J Urol, 36: 669, 1936 Jewett et al. J Urol, 55: 366, 1946

  8. Extent of Lymphadenectomy • Node positive patients can enjoy long term survival • 24% of grossly node positive disease survived 10 years without adjuvant therapy • More nodes removed correlates with improved survival Sanderson et al. Urol Oncol., 22: 205, 2004

  9. Extent of Lymphadenectomy • Likely no staging advantage to extending the node dissection above the aortic bifurcation • 33% of unsuspected nodes found at common iliacs • Practice patterns vary widely: a.) 40% of cystectomies have no LND b.) 12.7% of LND had <4 nodes removed Lymph node density (# pos nodes/total # nodes) Konety et al. J Urol, 170: 1765, 2003

  10. Extent of Pelvic Lymph Node Dissection IMA Genitofemoral nerve Genitofemoral nerve Aortic Nodes Common Iliac Nodes Hypogastric and Obturator Nodes

  11. Survival By Number Of Lymph Nodes Removed Herr et al. JCO, 22(14): 2781, 2004

  12. Postcystectomy survival by node status and number of nodes removed Herr, H. W. et al. J Clin Oncol; 22:2781-2789 2004

  13. Post Cystectomy Survival Herr, H. W. et al. J Clin Oncol; 22:2781-2789 2004

  14. Gold Standard • Open radical cystectomy (RC) is the gold standard for treatment of muscle-invasive bladder cancer.

  15. Minimally Invasive Bladder Cancer Surgery • Efforts to reduce the operative morbidity of RC have fostered interest in minimally invasive approaches. • Laparoscopic RC • Robot-assisted laparoscopic RC

  16. Concerns of Robotic Cystectomy? • Concerns regarding minimally invasive RC • Absence of long term oncologic outcomes • Absence of long term functional outcomes • Limited pelvic lymphadenectomy • Longer operative time • Increased cost Miller NL et al: World J Urol (2006) 24:180

  17. Outcome Measures of Minimally Invasive Bladder Surgery • Previous reports comparing open versus minimally invasive RC have focused on perioperative outcomes. • Blood loss • Operative time • Analgesic requirement • Time to regular diet • Length of hospital stay Hemal AK et al: Urol Clin N Am (2004) 31:719 Basillote JB et al: J Urol (2004) 172:489 Taylor GD et al: J Urol (2004) 172:1291 Galich A et al: JSLS (2006) 10:145 Rhee JJ et al: BJU Int (2006) 98:1059

  18. Comparison of Surgical Techniques • Lymph node yield • Margin status • However, direct comparison between open and minimally invasive RC of early oncologic parameters is lacking.

  19. Study Comparison • Comparison of perioperative and early pathologic outcomes in a consecutive series of open and robotic RCs at our institution.

  20. Methods • From February to December 2006, 43 consecutive patients underwent RC by a single surgeon at our institution. • 22 open • 21 robotic

  21. Technique • Posterior dissection • Isolation of ureters • Lateral dissection • Control of bladder pedicles • Anterior dissection • Control of DVC and division of urethra • Control of prostate pedicles and nerve-sparing • Pelvic lymph node dissection • External iliac, hypogastric, and obturator lymphadenectomy up to the level of the mid-common iliac vessels • Extracorporeal urinary diversion through a 5-7cm midline incision • Orthotopic neobladder: robot re-docked for urethral neovesical anastomosis

  22. Data Collection and Analysis • Data was collected prospectively • Patient characteristics • Perioperative outcomes • Early pathologic outcomes • Data analysis • Chi-square test • Fisher’s exact test • Student’s t-test

  23. Results: Patient Characteristics • There was no difference in the following parameters among the 2 cohorts. • Age • BMI • ASA class • Prior abdominal surgery • Prior abdominal radiation • Neoadjuvant chemotherapy

  24. Results: Clinical Stage

  25. Urinary Diversion

  26. Operative Time * P < 0.05

  27. Robotic Learning Curve * P < 0.05

  28. Blood Loss & Postoperative Parameters * P < 0.05

  29. Postoperative Complications

  30. Pathologic Stage * P < 0.05

  31. Node & Margin Status * P < 0.05

  32. Conclusions:Robotic Cystectomy • Increased operative time • significantly longer operative time in the robotic neobladder cohort (p=0.01) • Decreased operative time with increased experience • 450 to 338 min (p=0.007)

  33. Conclusions:Robotic Cystectomy • Decreased • Blood loss • Transfusion requirement • Time to regular diet • Length of hospital stay

  34. Conclusions:Robotic Cystectomy • Equivalent lymph node yield • 17.4 (robotic) vs. 18.9 (open), p=0.6 • Equivalent margin rate • 9% (robotic) vs. 19% (open), p=0.2 • Long term oncologic and functional outcomes are required Stein JP et al: J Urol (2003) 170: 35 Herr H et al: J Urol (2004) 171: 1823

  35. Minimally Invasive Cystectomy • Minimally Invasive = Cancer Sparing

  36. Prostate Sparing Cystectomy • Role for improved continence and potency • Need to rule out prostate cancer or TCC of prostatic urethra • Functional Results are good: a.) 97% complete continence b.) No episodes of retention c.) 82% maintained potency Vallancien et al. J Urol, 168: 2413, 2002

  37. Prostate Sparing Cystectomy • Incidence of Pca is 30-50% with approx. 48% are clinically significant • 60% of CaP involve the apex (79% significant and 42% insignificant) • 48% of prostates had urothelial ca involvement of which 33% had apical involvement • 61% had no prostatic apical involvement of CaP or Urothelial ca.

More Related